Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma

Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma

2024.03.14
In February 2024, a study led by Professor Gang An from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College was published in the international academic journal ——Cancer (IF=11.2). The title of the study is "Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma". The study meticulously investigates the implications of early relapse on the survival outcomes of patients, offering invaluable insights that promise to redefine treatment approaches for this complex and heterogeneous hematologic malignancy. By shedding light on the pivotal role of early relapse as a prognostic indicator, the research presents a new frontier in the tailored management of MM, aiming to improve the outcomes for patients worldwide.
MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities

MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities

2024.03.14
In January 2024, a groundbreaking study spearheaded by Professor Gang An  from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, made its debut in the esteemed journal Haematologica (IF=11.047). The research, titled "MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities" marks a significant advancement in the understanding of multiple myeloma (MM). This comprehensive investigation meticulously analyzes the prognostic impact of MAF translocations, t(14;16) and t(14;20), within the context of MM, shedding light on their independent prognostic significance despite the presence of other chromosomal anomalies. This study not only enhances the scientific community's comprehension of MM's genetic complexity but also paves the way for refining risk stratification and tailoring treatment approaches for affected patients, thereby contributing to the ongoing efforts to improve outcomes in this challenging hematological malignancy.
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial

Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial

2024.03.12
In July 2022, a study led by Professor Feng Xue et al. was published in the international academic journal ——Lancet Haematol. The title of the study is "Safety and activity of an engineered, liver-tropic…
Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

2024.03.08
In January 2024, a study led by Professor Ting Niu from West China Hospital, Sichuan University was published in the international academic journal ——Signal Transduction And Targeted Therapy (IF=38.104). The title of the study is "Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma". This study sheds light on the promising potential of FCRL5-directed CAR-T cell therapy in the treatment of multiple myeloma (MM).